A structure-activity analysis of biased agonism at the dopamine D2 receptor

Journal of Medicinal Chemistry

Volumn 56, Issue 22, 2013, Pages 9199-9221

  Shonberg, Jeremy ^a   Herenbrink, Carmen Klein ^a   López, Laura ^a   Christopoulos, Arthur ^a   Scammells, Peter J ^a   Capuano, Ben ^a   Lane, J Robert ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CARBAMIC ACID DERIVATIVE; CARIPRAZINE; DOPAMINE 2 RECEPTOR; SB 269652; TERT BUTYL(TRANS 4 [2 [3,4 DIHYDROISOQUINOLIN 2( 1H) YL]ETHYL)CYCLOHEXYL]CARBAMATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BIPOLAR DEPRESSION; CARBON NUCLEAR MAGNETIC RESONANCE; CHO CELL; DRUG ANALYSIS; DRUG EFFECT; DRUG STRUCTURE; DRUG SYNTHESIS; NONHUMAN; PARTIAL AGONISM; PROTON NUCLEAR MAGNETIC RESONANCE; SCHIZOPHRENIA; SIGNAL TRANSDUCTION; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION; THIN LAYER CHROMATOGRAPHY;

ANIMALS; CHO CELLS; CRICETINAE; CRICETULUS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; ISOQUINOLINES; MOLECULAR DOCKING SIMULATION; PROTEIN CONFORMATION; RECEPTORS, DOPAMINE D2; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84889247957     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm401318w     Document Type: Article

References (63)

1. Ma, P.; Zemmel, R. Value of novelty? Nat. Rev. Drug Discovery 2002, 1, 571-572
2. Lagerstrom, M. C.; Schioth, H. B. Structural diversity of G protein-coupled receptors and significance for drug discovery Nat. Rev. Drug Discovery 2008, 7, 339-357
3. Stevens, R. C.; Cherezov, V.; Katritch, V.; Abagyan, R.; Kuhn, P.; Rosen, H.; Wuthrich, K. The GPCR network: A large-scale collaboration to determine human GPCR structure and function Nat. Rev. Drug Discovery 2013, 12, 25-34
4. Stallaert, W.; Christopoulos, A.; Bouvier, M. Ligand functional selectivity and quantitative pharmacology at G protein-coupled receptors Expert Opin. Drug. Discovery 2011, 6, 811-825
5. Violin, J. D.; Lefkowitz, R. J. β-Arrestin-biased ligands at seven-transmembrane receptors Trends Pharmacol. Sci. 2007, 28, 416-422
6. Kenakin, T.; Christopoulos, A. Signalling bias in new drug discovery: Detection, quantification and therapeutic impact Nat. Rev. Drug Discovery 2013, 12, 205-216
7. Kenakin, T. Functional selectivity and biased receptor signaling J. Pharmacol. Exp. Ther. 2011, 336, 296-302
8. Urban, J. D.; Clarke, W. P.; von Zastrow, M.; Nichols, D. E.; Kobilka, B.; Weinstein, H.; Javitch, J. A.; Roth, B. L.; Christopoulos, A.; Sexton, P. M.; Miller, K. J.; Spedding, M.; Mailman, R. B. Functional selectivity and classical concepts of quantitative pharmacology J. Pharmacol. Exp. Ther. 2007, 320, 1-13 (Pubitemid 46025713)
9. Davis, K. L.; Kahn, R. S.; Ko, G.; Davidson, M. Dopamine in schizophrenia: A review and reconceptualization Am. J. Psychiatry 1991, 148, 1474-1486
10. 2 receptor-mediated signaling pathways Neuropsychopharmacology 2007, 32, 67-77 (Pubitemid 44967785)
11. 2 ligands for probing signal transduction pathways essential for antipsychotic efficacy Proc. Natl. Acad. Sci. U.S.A. 2011, 108, 18488-18493
12. 2 receptors Bioorg. Med. Chem. Lett. 2012, 22, 3437-3440
13. 3 receptors in vivo and shows antipsychotic-like and procognitive effects in rodents Neurochem. Int. 2011, 59, 925-935
14. 2 dopamine receptor antagonist-partial agonist antipsychotic candidate: In vitro and neurochemical profile J. Pharmacol. Exp. Ther. 2010, 333, 328-340
15. 3 receptor antagonist with high oral bioavailability and CNS penetration in the rat J. Med. Chem. 2000, 43, 1878-1885 (Pubitemid 30305020)
16. 3 receptor ligands. Patent WO 98/50364 A1, November 12, 1998.
17. 3 receptors. Patent WO 99/64412 A1, December 16, 1999.
18. 2 receptors Mol. Pharmacol. 2010, 78, 925-934
19. Kenakin, T.; Watson, C.; Muniz-Medina, V.; Christopoulos, A.; Novick, S. A simple method for quantifying functional selectivity and agonist bias ACS Chem. Neurosci. 2011, 3, 193-203
20. Rajagopal, S.; Ahn, S.; Rominger, D. H.; Gowen-MacDonald, W.; Lam, C. M.; DeWire, S. M.; Violin, J. D.; Lefkowitz, R. J. Quantifying ligand bias at seven-transmembrane receptors Mol. Pharmacol. 2011, 80, 367-377
21. Black, J. W.; Leff, P. Operational models of pharmacological agonism Proc. R. Soc. B. 1983, 220, 141-162 (Pubitemid 14217337)
22. Lane, J. R.; Sexton, P. M.; Christopoulos, A. Bridging the gap: Bitopic ligands of G-protein-coupled receptors Trends Pharmacol. Sci. 2013, 34, 59-66
23. Bock, A.; Merten, N.; Schrage, R.; Dallanoce, C.; Batz, J.; Klockner, J.; Schmitz, J.; Matera, C.; Simon, K.; Kebig, A.; Peters, L.; Muller, A.; Schrobang-Ley, J.; Trankle, C.; Hoffmann, C.; De Amici, M.; Holzgrabe, U.; Kostenis, E.; Mohr, K. The allosteric vestibule of a seven transmembrane helical receptor controls G-protein coupling Nat. Commun. 2012, 3, 1-11
24. 1-adrenergic receptor Nature 2011, 469, 241-244
25. 2 adrenoceptor Nature 2011, 469, 175-180
26. Rosenbaum, D. M.; Rasmussen, S. G. F.; Kobilka, B. K. The structure and function of G-protein-coupled receptors Nature 2009, 459, 356-363
27. 2-adrenergic receptor function Science 2007, 318, 1266-1273 (Pubitemid 350172885)
28. 2 adrenoceptor binding site with catechol reveals differences in binding and activation by agonists and partial agonists J. Biol. Chem. 2005, 280, 22165-22171 (Pubitemid 40827872)
29. 3 receptor agonists comprising an enyne moiety J. Med. Chem. 2013, 56, 5130-5141
30. 2 receptor agonists J. Med. Chem. 2012, 55, 7141-7153
31. 2L receptor functional selectivity induced by selected transmembrane 5 serine mutations Mol. Pharmacol. 2012, 81, 820-831
32. 2L receptor Mol. Pharmacol. 2011, 79, 575-585
33. 2L cell line: evidence for induction of ligand-specific receptor states Mol. Pharmacol. 2004, 66, 97-105 (Pubitemid 38822091)
34. 3 receptor binding, functional selectivity, and analysis of receptor-ligand interactions J. Med. Chem. 2011, 54, 2477-2491
35. 3 receptor J. Med. Chem. 2012, 55, 6689-6699
36. 2 dopamine receptors Biochem. Pharmacol. 2004, 67, 1657-1665 (Pubitemid 38479844)
37. Gottlieb, H. E.; Kotlyar, V.; Nudelman, A. NMR chemical shifts of common laboratory solvents as trace impurities J. Org. Chem. 1997, 62, 7512-7515
38. Mathe, T. B.; Hegedus, L.; Czibula, L.; Juhasz, B.; Nagy, B. J.; Markos, D. (Richter Gedeon NYRT, HU). A process for the preparation of trans aminocyclohexylacetic acid ethyl ester HCl. Patent WO 2010/070368 A1, June 24, 2010.
39. Wustrow, D.; Belliotti, T.; Glase, S.; Kesten, S. R.; Johnson, D.; Colbry, N.; Rubin, R.; Blackburn, A.; Akunne, H.; Corbin, A.; Davis, M. D.; Georgic, L.; Whetzel, S.; Zoski, K.; Heffner, T.; Pugsley, T.; Wise, L. Aminopyrimidines with high affinity for both serotonin and dopamine receptors J. Med. Chem. 1998, 41, 760-771 (Pubitemid 28114885)
40. Villani, F. J.; Ellis, C. A. 4-Dimethylaminodi(2-thienyl) cyclohexylcarbinol and related compounds J. Org. Chem. 1964, 29, 2585-2587
41. Takita, H.; Noda, S.; Mukaida, Y.; Kobayashi, H. 4-(Aminomethyl) cyclohexane-1-carboxylic acid derivatives. Patent EP 55145 A1, June 30, 1982.
42. 3 modulators and their preparation, pharmaceutical compositions and use in the treatment of CNS disorders. Patent WO 2007/093540 A1, August 23, 2007.
43. Ozaki, F.; Ishibashi, K.; Ikuta, H.; Ishihara, H.; Souda, S. (Eisai Co., Ltd., JP). Preparation of anthranilic acid amide derivative as cyclic guanosine monophosphate-phosphodiesterase inhibitors. Patent WO 95/18097 A1, July 6, 1995.
44. Cutrona, K. J.; Sanderson, P. E. J. The synthesis of thrombin inhibitor L-370,518 via an α-hydroxy-β-lactam Tetrahedron Lett. 1996, 37, 5045-5048 (Pubitemid 26315258)
45. Joossens, J.; Van der Veken, P.; Lambeir, A. M.; Augustyns, K.; Haemers, A. Development of irreversible diphenyl phosphonate inhibitors for urokinase plasminogen activator J. Med. Chem. 2004, 47, 2411-2413 (Pubitemid 38580077)
46. Lagisetti, C.; Pourpak, A.; Jiang, Q.; Cui, X.; Goronga, T.; Morris, S. W.; Webb, T. R. Antitumor compounds based on a natural product consensus pharmacophore J. Med. Chem. 2008, 51, 6220-6224
47. Ferber, E.; Bendix, H. 4-Aminocyclohexylacetic acid Ber. Dtsch. Chem. Ges. B 1939, 72B, 839-848
48. Hasumi, K.; Ohta, S.; Saito, T.; Sato, S.; Kato, J.-Y.; Sato, J.; Suzuki, H.; Asano, H.; Okada, M.; Matsumoto, Y.; Shirota, K. (Aska Pharmaceutical Co., Ltd., JP). Preparation of 5-amino-4-(4-pyrimidinyl)isoxazole derivatives as P38MAP kinase inhibitors and cytokine production inhibitors. Patent WO 2006/070927 A1, July 6, 2006.
49. Grunewald, G. L.; Dahanukar, V. H.; Caldwell, T. M.; Criscione, K. R. Examination of the role of the acidic hydrogen in imparting selectivity of 7-(aminosulfonyl)-1,2,3,4-tetrahydroisoquinoline (SK&F 29661) toward inhibition of phenylethanolamine N-methyltransferase vs the α2- adrenoceptor J. Med. Chem. 1997, 40, 3997-4005 (Pubitemid 28008394)
50. 2 receptor antagonists. Patent WO 2005/012266 A1, February 10, 2005.
51. 3 receptor agonists for treatment of CNS and ophthalmic disorders. Patent WO 03/029233 A1, April 10, 2003.
52. Canals, M.; Lane, J. R.; Wen, A.; Scammells, P. J.; Sexton, P. M.; Christopoulos, A. A Monod-Wyman-Changeux mechanism can explain G protein-coupled receptor (GPCR) allosteric modulation J. Biol. Chem. 2012, 287, 650-659
53. Ballesteros, J. A.; Weinstein, H. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. In Methods in Neurosciences; Sealfon, S. C., Ed.; Academic Press: San Diego, 1995; Vol. 25, pp 366-428.
54. Thompson, J. D.; Gibson, T. J.; Plewniak, F.; Jeanmougin, F.; Higgins, D. G. The CLUSTAL-X windows interface: Flexible strategies for multiple sequence alignment aided by quality analysis tools Nucleic Acids Res. 1997, 25, 4876-4882
55. 3 selective antagonist Science 2010, 330, 1091-1095
56. Sali, A.; Blundell, T. L. Comparative protein modelling by satisfaction of spatial restraints J. Mol. Biol. 1993, 234, 779-815 (Pubitemid 24007801)
57. Duan, Y.; Wu, C.; Chowdhury, S.; Lee, M. C.; Xiong, G.; Zhang, W.; Yang, R.; Cieplak, P.; Luo, R.; Lee, T.; Caldwell, J.; Wang, J.; Kollman, P. A point-charge force field for molecular mechanics simulations of proteins based on condensed-phase quantum mechanical calculations J. Comput. Chem. 2003, 24, 1999-2012
58. Wang, J.; Wolf, R. M.; Caldwell, J. W.; Kollman, P. A.; Case, D. A. Development and testing of a general amber force field J. Comput. Chem. 2004, 25, 1157-1174
59. Phillips, J. C.; Braun, R.; Wang, W.; Gumbart, J.; Tajkhorshid, E.; Villa, E.; Chipot, C.; Skeel, R. D.; Kalé, L.; Schulten, K. Scalable molecular dynamics with NAMD J. Comput. Chem. 2005, 26, 1781-1802 (Pubitemid 43078511)
60. MacKerell, A. D., Jr; Bashford, D.; Bellott, M.; Dunbrack, R. L., Jr; Evanseck, J. D.; Field, M. J.; Fischer, S.; Gao, J.; Guo, H.; Ha, S.; Joseph-McCarthy, D.; Kuchnir, L.; Kuczera, K.; Lau, F. T. K.; Mattos, C.; Michnick, S.; Ngo, T.; Nguyen, D. T.; Prodhom, B.; Reiher, W. E., III; Roux, B.; Schlenkrich, M.; Smith, J. C.; Stote, R.; Straub, J.; Watanabe, M.; Wiórkiewicz-Kuczera, J.; Yin, D.; Karplus, M. All-atom empirical potential for molecular modeling and dynamics studies of proteins J. Phys. Chem. B 1998, 102, 3586-3616 (Pubitemid 128576688)
61. Christopoulos, A. Assessing the distribution of parameters in models of ligand-receptor interaction: To log or not to log Trends Pharmacol. Sci. 1998, 19, 351-357 (Pubitemid 29011723)
62. Leff, P.; Prentice, D. J.; Giles, H.; Martin, G. R.; Wood, J. Estimation of agonist affinity and efficacy by direct, operational model-fitting J. Pharmacol. Methods 1990, 23, 225-237 (Pubitemid 20134917)
63. Motulsky, H. J.; Ransnas, L. A. Fitting curves to data using nonlinear regression: a practical and nonmathematical review FASEB J. 1987, 1, 365-74